Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. ( DAWN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Lauren Merendino - Chief Commercial Officer Charles York - COO & CFO Michael Vasconcelles - Head of Research & Development Conference Call Participants Tara Bancroft - TD Cowen, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and welcome to Day One Biopharmaceuticals Third Quarter 2025 Financial and Operating Results Conference Call.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.38 per share a year ago.
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 241.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last?
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)
OJEMDA's strong efficacy and expanding market share in pLGG, plus a robust cash runway, position Day One for significant upside if FIREFLY-2 succeeds. Current valuation is deeply discounted, reflecting modest launch, small TAM, and confirmatory trial risk, but underappreciates asymmetric reward potential. Early sales growth is solid, though moderating; future catalysts hinge on FIREFLY-2 results, EU approval, and DAY301 pipeline progress.
Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Charles N. York - COO & CFO Jeremy Bender - CEO, President & Director Joey Perrone - Corporate Participant Lauren Merendino - Chief Commercial Officer Michael Vasconcelles - Corporate Participant Conference Call Participants Alec Warren Stranahan - BofA Securities, Research Division Andrea R.
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301
DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upside, while continued sluggishness risks further stock stagnation or decline. Potential European approval for Ojemda and phase 1 data from a trial of DAY-301 represent other catalysts ahead, but likely won't provide much news this quarter.
Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Alec Stranahan - Bank of America Soumit Roy - Jones Research Andrea Newkirk - Goldman Sachs Andres Maldonado - H.C. Wainwright Operator Ladies and gentlemen, thank you for standby.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.
